BioSpace News Archive

Hyloris Pharmaceuticals SA announces Maxigesic® IV has been approved for the relief of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics in adults, where an intravenous route of administration is considered clinically necessary.

Aculys Pharma, Inc. announced that it has achieved its primary efficacy endpoint in a pre-specified interim analysis of its Phase 3 clinical study of a diazepam nasal spray, an antiepileptic drug for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus targeting Japanese patients aged 6 to 17 years.

Sosei Group Corporation is pleased to announce its President & CEO, Chris Cargill has won Executive of the Year for the second year running at the Citeline Pharma Intelligence Awards Japan 2023 held yesterday in Tokyo.

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.

Tonix Pharmaceuticals Holding Corp. today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.

Axogen, Inc. today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens.

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.

ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories, which manages and operates the national laboratory at Chalk River, Ontario on behalf of Atomic Energy of Canada Limited, announced the launch of Actineer™ Inc., a new joint venture company between CNL and ITM for the industrial scale production of Actinium-225.

Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing platform, announced participation at the upcoming Leerink Biopharma Private Company Connect, taking place virtually from October 25 – 26, 2023.

DENTSPLY SIRONA Inc. announced that the Company will be hosting an investor conference call and live webcast on Thursday, November 2, 2023, at 8:30 am ET to review its third quarter financial results.